Economic outcomes · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at 3 months after surgery · patients undergoing cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Central retinal thickness at 3 months after surgery; · patients undergoing cataract surgery
1 finding from 1 review
Adverse effects · patients undergoing cataract surgery
1 finding from 1 review
MO at 3 months after cataract surgery, clinically symptomatic, · patients undergoing cataract surgery
NSAIDS may leads to lower MO at 3 months after cataract surgery; clinically symptomatic compared with steroids (low certainty).
1 finding from 1 review
Mean postoperative best‐corrected visual acuity · patients undergoing cataract surgery
1 finding from 1 review
Poor vision due to MO at 3 months after surgery · patients undergoing cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Poor vision due to MO at 12 months after surgery · patients undergoing cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 12 to 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.23 [2.36, 7.59]
Studies not reported
Moderate
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.76 [2.84, 7.99]
Studies not reported
Moderate
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
It is very uncertain whether intravitreal dexamethasone implant 0.7 mg changes surgery for glaucoma ‐ 24 months compared with intravitreal antiVEGF (very low certainty).
1 finding from 1 review
RR 3.02 [0.12, 73.56]
Studies not reported
Very low
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).
1 finding from 1 review
Change in retinal thickness (micron) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher cataract progression ‐ 24 months compared with sham (moderate certainty).
1 finding from 1 review
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with sham (moderate certainty).
1 finding from 1 review
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg may leads to higher surgery for glaucoma ‐ 24 months compared with sham (low certainty).
1 finding from 1 review
Visual acuity · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg showed no clear difference in gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).
1 finding from 1 review